top of page
About
Crosshair Therapeutics harnesses machine learning and a novel high-precision protein targeting technology to design a new class of DNA-based therapeutics computationally. Crosshair's unique platform enables unrestricted access to the most difficult disease targets.
What Founders say:
Michael Bruno
CEO & Co-Founder
"We have identified a number of strategies to commercialize the different drugs and programs that we have, and we’re looking for help with our commercialization and go-to-market strategy, specifically companies we should reach out to, how we should do that. We are looking forward to joining the M7 cohort!"
bottom of page